StonvexLoading…
StonvexStonvexStonvexCore line items from DBD's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2023 2023-08-12 |
|---|---|---|---|---|
Revenue | $3.81B | $3.75B | $1.63B | $2.13B |
Operating Income | $242.00M | $182.10M | $92.40M | $-5.50M |
Net Income | $94.60M | $-16.50M | $13.40M | $1.36B |
EPS (Diluted) | $2.54 | $-0.44 | $0.36 | $16.69 |
Total Assets | $3.85B | $3.54B | $4.16B | $4.18B |
Total Liabilities | $2.75B | $2.61B | $3.08B | $3.13B |
Cash & Equivalents | $368.90M | $296.20M | $550.20M | $391.40M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 35.38M | 37.58M | 37.57M | 81.40M |